Outcomes of early enteral feeding in very low birth weight infants: A meta-analysis of randomized controlled trials.

Pediatr NeonatolMay 18, 2026 (epub)
Clinical ResearchPediatrics

Amani N Alansari, Marwa Messaoud, Alaa Ahmed Elshanbary et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated early enteral feeding in very low birth weight (VLBW) infants using data from 17 randomized controlled trials. The study found that early feeding (≤72 hours) did not significantly increase mortality or necrotizing enterocolitis risk, but was associated with a reduction in sepsis incidence (RR = 0.78) and a shorter time to full enteral feeding (MD = -2.72 days).

Key findings

  • Early feeding did not significantly increase mortality (RR = 0.72; 95% CI: 0.51 to 1.01).
  • There was a significant reduction in sepsis incidence (RR = 0.78; 95% CI: 0.61 to 0.98).
  • Early feeding shortened the time to full enteral feeding by an average of 2.72 days (MD = -2.72 days; 95% CI: -5.08 to -0.36).
  • No significant differences were found in the incidence of intraventricular hemorrhage or gastrointestinal bleeding.

Why it matters

Understanding the impact of early enteral feeding on VLBW infants is crucial for optimizing neonatal care. This study suggests that early feeding may not pose additional risks and could lead to improved feeding timelines and reduced sepsis rates.

Source

Published in Pediatr Neonatol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.